![[Podcast] Trial Trailblazers: Behind clinical breakthroughs](https://imgproxy.divecdn.com/cr_gUY8HHfHKWVfM5mEkCyXB9OzVqKd0L_Zq5ZJQSoM/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlX1BvZGNhc3RfY292ZXIxMzQ2eDcyOV9SMi5wbmc=.webp)
FDA limits Merck's Keytruda, Bristol Myers' Opdivo in stomach cancer
After questioning the benefits of checkpoint inhibitors in stomach cancer cases without PD-L1 expression, the FDA has moved to restrict the use of Merck's and Bristol Myers Squibb's immunotherapies in those patients.
After questioning the benefits of checkpoint inhibitors in stomach cancer cases without PD-L1 expression, the FDA has moved to restrict the use of Merck's and Bristol Myers Squibb's immunotherapies in those patients.
